Humana Inc. (NYSE:HUM – Free Report) – Investment analysts at Zacks Research decreased their Q1 2027 EPS estimates for Humana in a research note issued to investors on Wednesday, April 15th. Zacks Research analyst Team now forecasts that the insurance provider will earn $8.98 per share for the quarter, down from their prior estimate of $8.99. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q2 2027 earnings at $6.34 EPS and Q3 2027 earnings at $0.70 EPS.
Other equities research analysts have also recently issued reports about the stock. Sanford C. Bernstein restated an “outperform” rating and set a $344.00 price target on shares of Humana in a report on Tuesday, January 6th. Guggenheim decreased their price target on shares of Humana from $312.00 to $252.00 and set a “buy” rating for the company in a report on Thursday, February 12th. UBS Group restated a “neutral” rating on shares of Humana in a report on Wednesday, February 25th. Truist Financial upped their price target on shares of Humana from $200.00 to $220.00 and gave the company a “hold” rating in a report on Monday. Finally, Barclays decreased their price target on shares of Humana from $245.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $222.09.
Humana Stock Up 1.2%
HUM stock opened at $200.66 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00. Humana has a 52-week low of $163.11 and a 52-week high of $315.35. The company has a 50-day moving average of $181.09 and a two-hundred day moving average of $231.32. The stock has a market capitalization of $24.09 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 2.13 and a beta of 0.44.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. During the same period in the prior year, the company posted ($2.16) earnings per share. Humana’s revenue for the quarter was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS.
Humana Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.8%. Humana’s dividend payout ratio is currently 36.05%.
Insider Activity at Humana
In related news, insider Sanjay K. Shetty acquired 810 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the transaction, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Montag A & Associates Inc. raised its position in shares of Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the last quarter. CoreCap Advisors LLC raised its position in shares of Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares during the last quarter. Fideuram Asset Management Ireland dac acquired a new position in shares of Humana during the fourth quarter valued at about $27,000. Reflection Asset Management acquired a new position in shares of Humana during the fourth quarter valued at about $29,000. Finally, Rosenberg Matthew Hamilton raised its position in shares of Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.
More Humana News
Here are the key news stories impacting Humana this week:
- Positive Sentiment: Board-approved quarterly dividend ($0.885/share) reinforces cash return to shareholders and supports yield-focused demand; dividend payable July 31 with record date June 26. Humana Board Declares Payment of Quarterly Dividend to Stockholders
- Positive Sentiment: Truist raised its price target to $220, which signals some analyst conviction in Humana’s recovery potential and can provide buying interest from momentum/target-driven investors. Truist Financial Increases Humana (NYSE:HUM) Price Target to $220.00
- Positive Sentiment: Jim Cramer discussed Humana’s sizable business on TV — positive media coverage can boost retail attention and short-term demand. Jim Cramer Discusses Big Humana (HUM) Business
- Positive Sentiment: Humana-backed research (telephone training for COPD patients) highlights clinical outcomes and value-based care initiatives that support long-term Medicare Advantage positioning. This is favorable for investor sentiment around durable growth drivers. On the Line for Lung Health: Telephone Training Helps COPD Patients Perfect Inhaler Use
- Neutral Sentiment: Robert W. Baird trimmed its price target to $205 from $264 but kept a “neutral” rating — reduces upside implied by some analysts but is less severe than an outright sell call. Baird adjusts price target on Humana to $205 from $264; maintains neutral rating
- Negative Sentiment: Zacks Research downgraded HUM to “Strong Sell” and nudged down Q1–Q3 2027 EPS estimates slightly — a headline downgrade can prompt short-term selling pressure and influence sentiment among institutional managers. Zacks Research downgrade coverage
- Negative Sentiment: Data breach impacting Humana customers across Texas and five other states introduces reputational risk, potential remediation costs and regulatory scrutiny — a material negative for near-term risk perception. Data breach hits Humana customers in Texas, five other states
About Humana
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
See Also
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
